KDR and Parkinson disease: This study aimed to test whether adropin administration affects the 6-OHDA-induced PD model of rats and subsequently determine whether it depends on VEGFR2 or GPR19 receptors and activation of intracellular pathways associated with these receptors, which offers a potential therapy for PD.